Arboretum Ventures and Hatteras Venture Partners led a $20m Series B round in Boomerang Medical.

Arboretum Ventures, a healthcare venture capital firm, and Hatteras Venture Partners, a capital venture firm, led a $20m Series B round in Boomerang Medical, a bioelectronic medical enterprise. "Ulcerative colitis patients struggle with symptoms that profoundly affect their daily lives. Our pivotal trial asks a simple but critical question: can this therapy meaningfully reduce symptom burden and improve quality of life for people living with ulcerative colitis? With the continued support of our investors, we're pursuing that answer for patients and their physicians," Heather Simonsen, Boomerang Medical CEO.